A perpetual loser at the high stakes game of Alzheimer's research, Roche concedes another amyloid flop
The amyloid beta theory that has driven billions of dollars in failed Alzheimer’s research has taken yet another body blow.
Roche — and specifically its big sub Genentech — conceded defeat overnight for its closely watched Phase II API-ADAD trial of crenezumab in Alzheimer’s prevention. This follows twin Phase III failures — CREAD 1 and CREAD 2 in 2019 — and may well effectively mark the end of the line for a drug in-licensed from Switzerland’s AC Immune 16 years ago.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
